HEPION PHARMACEUTICALS, INC. Preferred Stock Dividends, Income Statement Impact
HEPION PHARMACEUTICALS, INC. (HEPA) reported Preferred Stock Dividends, Income Statement Impact of $7.84 million for the 12-month period ending 2015-06-30, per its 10-K filed 2016-09-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2016-09-28
- HEPION PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2015-06-30 was $0.00.
- HEPION PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2015-03-31 was $3.00M.
- HEPION PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2014-12-31 was $4.84M.
- HEPION PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for fiscal 2015 was $7.84M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $3.00M derived: sum of 2 quarters · filed 2016-09-28 | $7.84M derived: sum of 3 quarters · filed 2016-09-28 | $7.84M 10-K · filed 2016-09-28 |
| 2015-03-31 | $3.00M 10-Q · filed 2016-05-13 | $7.84M derived: sum of 2 quarters · filed 2016-05-13 | $7.84M 10-Q · filed 2016-05-13 | |
| 2014-12-31 | $4.84M 10-Q · filed 2016-02-12 | $4.84M 10-Q · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |